PTC Study to Evaluate Ataluren in Combination With Ivacaftor

Phase 4

Completed

Brief Summary: The purpose of this study is to explore the combination of ataluren and ivacaftor as a treatment for patients with nonsense mutation cystic fibrosis

Detailed Description: Cystic Fibrosis (CF) is a life threatening genetic disorder resulting from mutations found in the CF gene known as the cystic fibrosis transmembrane conductance regulator or CFTR. This defect prevents correct chloride absorption in and out of the cells The purpose of this study is to explore the combination of ataluren and ivacaftor as a treatment for patients with a specific cystic fibrosis mutation

Recruitment & Eligibility

Inclusion Criteria

Evidence of signed and dated informed consent/assent document(s) indicating that the subject (and/or his parent/legal guardian) has been informed of all pertinent aspects of the trial.
Age ≥6 years
Body weight ≥16 kg
Diagnosis of cystic fibrosis and documentation of the presence of a nonsense mutations of the CFTR gene, as determined by historical genotyping
Ability to perform a valid, reproducible spirometry with demonstration of a forced expiratory volume in 1second (FEV1) ≥30% and ≤90% of predicted for age, gender, and height.
If the subject is sexually active, willingness to abstain from sexual intercourse or employ a barrier or medical method of contraception during the study drug administration
Willingness and ability to comply with all study procedures and assessments.
Currently being administered ivacaftor, either alone (Kalydeco) or in combination with lumacaftor (Orkambi)

Exclusion Criteria

Any change (initiation, change in type of drug, dose modification, schedule modification, interruption, discontinuation, or re-initiation) in a chronic treatment/prophylaxis regimen for CF or for CF-related conditions within 2 weeks prior to screening.
Ongoing participation in any other therapeutic clinical trial.
Evidence of pulmonary exacerbation or acute upper or lower respiratory tract infection (including viral illnesses) within 2 weeks prior to screening.
Ongoing inhaled tobramycin therapy.
Ongoing immunosuppressive therapy (other than corticosteroids up to 10mg/d equivalent of prednisone)
Ongoing warfarin, phenytoin, or tolbutamide therapy.
History of solid organ or hematological transplantation.
A history of positive hepatitis B surface antigen test, hepatitis C antibody test, or human immunodeficiency
Major complications of lung disease (including massive hemoptysis, pneumothorax, or pleural effusion) within 4 weeks prior to screening.
Pregnancy or breast-feeding.
Current smoker or a smoking history of ≥10 pack-years (number of cigarette packs/day × number of years smoked).
Prior or ongoing medical condition (eg, renal failure, alcoholism, drug abuse, psychiatric condition), medical history, physical findings, ECG findings, or laboratory abnormality that, in the investigator's opinion, could adversely affect the safety of the subject, makes it unlikely that the course of treatment or follow-up would be completed, or could impair the assessment of study results.

Arm && Interventions

Group	Intervention	Description
ataluren administration	Ataluren	dose of the drug administered (mg/kg body weight)

Primary Outcome Measures

Name	Time	Method
FEV1 as a Measure of Lung Function	1 year	effect of ataluren on lung function as assessed by spirometry and measured by percentage of Liters (minimum value would be .0% Liters and maximum value of liters is dependent from person to person). The higher the value the better the outcome. The measure will include the change from baseline to one year to report a change between the two measurement points

Secondary Outcome Measures